Edison Investment Research Limited
London, UK, 25 June 2025
Edison issues report on Worldwide Healthcare Trust (WWH) Edison issues report on Worldwide Healthcare Trust (LSE: WWH). Worldwide Healthcare Trust (WWH) is celebrating its 30-year anniversary. While recent performance is not what co-managers Sven Borho and Trevor Polischuk at global healthcare specialist OrbiMed would have wished for, this should be put into perspective. Since its launch in April 1995 until the end of FY25 (31 March), the trust has generated average annual NAV total returns of 13.4%. WWH has also outperformed its benchmark by a considerable margin over this period. The managers retain a positive outlook for the healthcare sector, including for biotech stocks, which have been the primary reason for WWH’s underperformance. The trust’s performance is yet to recover from a tough period between Q121 and Q222 when growth stocks, including biotech, came under pressure in a rising interest rate environment. Click here to read the full report. All reports published by Edison are available to download free of charge from its website Edison is authorised and regulated by the Financial Conduct Authority. Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities. For more information, please contact Edison: Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/ YouTube www.youtube.com/edisonitv
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. |
2160464 25-Jun-2025
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.